Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches.

Publication ,  Journal Article
D'Alessio, DA; Vahl, TP
Published in: Curr Diab Rep
October 2005

Glucagon-like peptide-1 (GLP-1) is an intestinal hormone that promotes glucose homeostasis through the regulation of insulin and glucagon secretion, gastric emptying, and food intake. This spectrum of effects makes GLP-1 an attractive candidate for drug development. However, because GLP-1 is a small peptide with rapid metabolism in the circulation, its usefulness to treat patients is limited. However, GLP-1 mimetics that are resistant to degradation have been developed and are effective in lowering blood glucose in diabetic patients. A second strategy for harnessing GLP-1 therapeutically is to inhibit the metabolism of endogenous GLP-1; several orally available compounds are in clinical trials. These two new classes of drugs both enhance GLP-1 signaling but differ in several key characteristics that may lead to distinct roles in the treatment of diabetic patients.

Duke Scholars

Published In

Curr Diab Rep

DOI

ISSN

1534-4827

Publication Date

October 2005

Volume

5

Issue

5

Start / End Page

346 / 352

Location

United States

Related Subject Headings

  • Venoms
  • Signal Transduction
  • Receptors, Glucagon
  • Protease Inhibitors
  • Peptides
  • Glycoproteins
  • Glucagon-Like Peptide-1 Receptor
  • Glucagon-Like Peptide 1
  • Exenatide
  • Endocrinology & Metabolism
 

Citation

APA
Chicago
ICMJE
MLA
NLM
D’Alessio, D. A., & Vahl, T. P. (2005). Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches. Curr Diab Rep, 5(5), 346–352. https://doi.org/10.1007/s11892-005-0092-2
D’Alessio, David A., and Torsten P. Vahl. “Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches.Curr Diab Rep 5, no. 5 (October 2005): 346–52. https://doi.org/10.1007/s11892-005-0092-2.
D’Alessio, David A., and Torsten P. Vahl. “Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches.Curr Diab Rep, vol. 5, no. 5, Oct. 2005, pp. 346–52. Pubmed, doi:10.1007/s11892-005-0092-2.
Journal cover image

Published In

Curr Diab Rep

DOI

ISSN

1534-4827

Publication Date

October 2005

Volume

5

Issue

5

Start / End Page

346 / 352

Location

United States

Related Subject Headings

  • Venoms
  • Signal Transduction
  • Receptors, Glucagon
  • Protease Inhibitors
  • Peptides
  • Glycoproteins
  • Glucagon-Like Peptide-1 Receptor
  • Glucagon-Like Peptide 1
  • Exenatide
  • Endocrinology & Metabolism